Torino-based Resalis raises €10 million Series A to provide a therapeutic that reduces fat mass in obesity

Published on January 4, 2024

Resalis Therapeutics, an Italian company tackling metabolic disorders with non-coding RNAs, announced the closing of a €10 million Series A financing round led by Sunstone Life Science Ventures with participation from existing investors including Claris Ventures and angel investors. The proceeds will be used to initiate and complete the first-in-human Phase 1 clinical trial and…

This content is for members only. Visit the site and log in/register to read.

The post Torino-based Resalis raises €10 million Series A to provide a therapeutic that reduces fat mass in obesity appeared first on EU-Startups.

Continue reading on website
Other news

Sustainability beyond rhetoric: Navigating authentic commitments in a greenwashing era

January 4, 2024
In an era where environmental consciousness shapes consumer choices, the quest for products and services aligned with eco-friendly values has surged. However, this noble pursuit has birthed a concerning trend towards greenwashing, leading to dubious marketing strategies employed by companies, often exaggerating their sustainability commitments to woo customers. Shockingly, according to a European

2024 Buy or Hold Chemical Stocks?

January 4, 2024
The chemical industry stands on the cusp of substantial growth, driven by robust demand across vital sectors. Therefore, let’s assess the prospects of chemical stocks Dow Inc. (DOW), Linde plc...